[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 4 of about 4
1. Yokoyama M, Nakao Y, Iwasaka T, Pater A, Sugimori H: Retinoic acid and interferon-alpha effects on cell growth and differentiation in cervical carcinoma cell lines. Obstet Gynecol; 2001 Aug;98(2):332-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Cell growth rate was examined after treatment for 4, 7, and 10 days with RA and/or IFN-alpha of human papillomavirus type 18 (HPV 18)-immortalized endo- and ectocervical cells, nontransformed serum-adapted cells, transformed cells, three adenocarcinoma, and three squamous cell carcinoma cell lines.
  • RESULTS: Cell growth rate was inhibited by RA, 84-96% in HPV 18-immortalized endocervical cells, SiHa, and ME180, 0% in OMC-4, and 18-62% in other cell lines; and by IFN-alpha about 75% in SiHa and ME180 and 14-40% in the other cell lines.
  • In rafts, RA treatment reversed human endocervical cell metaplasia and HPV 18-immortalized endo- and ectocervical cell dysplastic epithelial differentiation.
  • CONCLUSION: Cell growth inhibition by treatment with RA, IFN-alpha, and their combination differentially depends on treatment type and time, cell origin, cell line, and oncogenic state.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Interferon-alpha / pharmacology. Tretinoin / pharmacology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Apoptosis / drug effects. Carcinoma, Squamous Cell / pathology. Cell Differentiation / drug effects. Cell Division / drug effects. Cell Line, Transformed. Cervix Uteri / cytology. Cervix Uteri / drug effects. Female. Humans. Papillomaviridae. Tumor Cells, Cultured / drug effects


2. Miller B, Dunn J, Dalrymple J, Krivak TC: Pelvic sidewall adenocarcinoma after definitive therapy for cervical adenocarcinoma in situ. Gynecol Oncol; 2005 Nov;99(2):489-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelvic sidewall adenocarcinoma after definitive therapy for cervical adenocarcinoma in situ.
  • BACKGROUND: Traditionally, hysterectomy is considered definitive therapy for cervical adenocarcinoma in situ (AIS) in women beyond childbearing.
  • CASE: A 45-year-old gravida 2, para 2 patient presented with cervical dysplasia and on pathology review of the large loop excision procedure cervical adenocarcinoma in situ was diagnosed.
  • Final pathology revealed adenocarcinoma in situ with negative margins.
  • A CT-guided biopsy of the mass was consistent with invasive adenocarcinoma of the endocervical type.
  • Despite undergoing definitive surgery, a residual focus of disease may remain leading to invasive adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma in Situ / surgery. Pelvic Neoplasms / pathology. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Hysterectomy. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy


3. Kos M, Sarkanj-Golub R, Cupić H, Balicević D: [The correlation of inflammation and epithelial changes in the Pap smears of cervix uteri]. Acta Med Croatica; 2005;59(4):297-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: The aim of this study was to assess the number and type of cytologic abnormalities of uterine cervix classified according to Zagreb 1990, on routinely examined Pap smears during the 6-year period, and to investigate the connection of these abnormalities with lower genital tract infections.
  • Endocervical adenocarcinoma was cytologically diagnosed in only 0.0055% of all Pap smears examined.
  • Of specific causative agents HPV and Chlamydia trachomatis were significantly more frequently found in the group with epithelial dysplasia/carcinoma than in the control group (p < 0.05 both), however, Gardnerella vaginalis, Trichomonas vaginalis or Candida yielded no significant differences.


Advertisement
4. Cambruzzi E, Zettler CG, Alexandre CO: Expression of Ki-67 and squamous intraepithelial lesions are related with HPV in endocervical adenocarcinoma. Pathol Oncol Res; 2005;11(2):114-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Ki-67 and squamous intraepithelial lesions are related with HPV in endocervical adenocarcinoma.
  • To estimate the association between human papillomavirus (HPV) status and the expression of p53, Ki-67 and bcl-2 in cases of endocervical adenocarcinoma, and the relation with squamous intraepithelial lesions (SIL) and age, 229 cases were selected, treated between 1995 and 2003 in the Hospital Nossa Senhora da Conceiçao.
  • The joint occurrence of endocervical adenocarcinoma and SIL were estimated too.
  • The presence of HPV, especially type 18 in endocervical adenocarcinoma suggests that this agent can be an important cofactor in the development and progression of glandular neoplasms of the uterine cervix.
  • The joint occurrence of endocervical adenocarcinoma and SIL may support this hypothesis.
  • HPV may promote an increased proliferation index in endocervical adenocarcinoma, shown by the expression of Ki-67.
  • [MeSH-major] Adenocarcinoma / virology. Ki-67 Antigen / metabolism. Papillomaviridae / pathogenicity. Papillomavirus Infections / pathology. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / virology. Cell Proliferation. Cervical Intraepithelial Neoplasia / metabolism. Cervical Intraepithelial Neoplasia / pathology. Cervical Intraepithelial Neoplasia / virology. Cervix Uteri / metabolism. Cervix Uteri / pathology. Cervix Uteri / virology. DNA, Viral / analysis. Female. Humans. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Obstet Gynecol Scand. 2003 Oct;82(10):960-5 [12956848.001]
  • [Cites] Gynecol Oncol. 1990 Feb;36(2):246-9 [2298414.001]
  • [Cites] Diagn Cytopathol. 1995 Dec;13(5):379-85 [8834311.001]
  • [Cites] Am J Clin Pathol. 1989 Nov;92(5):577-82 [2554717.001]
  • [Cites] Int J Cancer. 1998 Feb 9;75(4):536-45 [9466653.001]
  • [Cites] Gynecol Oncol. 2003 Sep;90(3):547-51 [13678722.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1079-85 [10613340.001]
  • [Cites] Int J Gynecol Pathol. 2002 Apr;21(2):125-33 [11917221.001]
  • [Cites] Gynecol Oncol. 2002 Jul;86(1):14-8 [12079293.001]
  • [Cites] Int J Gynecol Pathol. 1995 Jul;14(3):209-16 [8600071.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1655-60 [12168850.001]
  • [Cites] Gynecol Oncol. 2000 Apr;77(1):129-36 [10739702.001]
  • [Cites] Hum Pathol. 1997 Mar;28(3):309-15 [9042795.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jan;23(1):1-6 [14668542.001]
  • [Cites] J Clin Oncol. 1996 Jul;14(7):2120-30 [8683245.001]
  • [Cites] Am J Epidemiol. 2004 May 1;159(9):834-42 [15105176.001]
  • [Cites] Cancer. 2002 Feb 25;96(1):5-13 [11836697.001]
  • [Cites] Mod Pathol. 2000 Mar;13(3):243-51 [10757335.001]
  • [Cites] Histopathology. 2002 Sep;41(3):185-207 [12207781.001]
  • [Cites] Histopathology. 2002 Oct;41(4):313-21 [12383213.001]
  • [Cites] Eur J Gynaecol Oncol. 2001;22(6):420-2 [11874072.001]
  • [Cites] Gynecol Oncol. 2003 Jul;90(1):15-22 [12821336.001]
  • [Cites] Mod Pathol. 1997 Mar;10(3):176-80 [9071723.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):884-91 [11420459.001]
  • [Cites] Int J Gynaecol Obstet. 1998 Dec;63(3):265-70 [9989896.001]
  • [Cites] Am J Obstet Gynecol. 1998 Jan;178(1 Pt 1):113-7 [9465813.001]
  • [Cites] J Clin Pathol. 2004 Jan;57(1):68-72 [14693839.001]
  • [Cites] J Clin Pathol. 1996 Dec;49(12):957 [9038727.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2297-303 [8635035.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):545-60 [7677168.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Mar;10(3):171-7 [11303584.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):51-8 [14529662.001]
  • [Cites] Cancer. 2000 Sep 15;89(6):1291-9 [11002225.001]
  • [Cites] Am J Clin Oncol. 2001 Apr;24(2):160-6 [11319292.001]
  • [Cites] Gynecol Oncol. 1999 Jul;74(1):53-60 [10385551.001]
  • [Cites] Gynecol Oncol. 2001 Aug;82(2):238-46 [11531273.001]
  • [Cites] Eur J Cancer. 2001 Jan;37(2):246-50 [11166153.001]
  • [Cites] Ann Oncol. 2000 Jun;11(6):647-63 [10942052.001]
  • [Cites] Acta Obstet Gynecol Scand. 2003 Aug;82(8):762-6 [12848649.001]
  • [Cites] APMIS. 2000 Mar;108(3):209-15 [10752690.001]
  • [Cites] Gynecol Oncol. 1989 Apr;33(1):49-53 [2703167.001]
  • [Cites] Int J Gynecol Pathol. 1999 Jul;18(3):215-9 [12090589.001]
  • [Cites] Hum Pathol. 2000 Nov;31(11):1339-40 [11112206.001]
  • [Cites] Pathol Oncol Res. 1999;5(2):95-103 [10393359.001]
  • [Cites] Int J Gynecol Pathol. 1993 Jan;12(1):64-9 [8380284.001]
  • [Cites] Ann Med. 2003;35(7):458-65 [14649328.001]
  • [Cites] Diagn Cytopathol. 1998 Jun;18(6):393-7 [9626509.001]
  • [Cites] Int J Gynecol Pathol. 1997 Jan;16(1):22-7 [8986528.001]
  • [Cites] Hum Pathol. 2002 Sep;33(9):899-904 [12378514.001]
  • (PMID = 15999157.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down






Advertisement